SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials - PubMed
5 hours ago
- #Obesity Research
- #Real-World Evidence
- #Semaglutide
- The SEMASEARCH study is a retrospective multicenter observational cohort evaluating real-world effectiveness of semaglutide 2.4 mg in adults with severe obesity (BMI ≥ 40 kg/m² with at least one treated obesity-related complication).
- It includes 1100 patients from 11 French obesity centers, with data collected at baseline, 6 months, and 12 months, focusing on underrepresented subgroups like those with bariatric surgery history, binge eating disorder, hypothalamic obesity, age ≥ 60 years, BMI ≥ 60 kg/m², and psychotropic medication use.
- Primary outcome is body weight change at 6 and 12 months; secondary outcomes include clinically meaningful weight loss (≥10%), metabolic improvements, patient-reported outcomes, body composition changes, and tolerance.
- The study aims to assess weight loss predictors using machine learning and address knowledge gaps in clinically complex populations underrepresented in clinical trials.